PUVA Therapy: Immunologic and Genotoxic Approaches to Risk Evaluation

  • G. H. S. Strauss


PUVA (psoralen and near ultraviolet light) is a DNA-damaging, clinically effective treatment. If we have patience, studies of PUVA therapy should give us a rare opportunity to learn much about not only the diseases it treats, but also about diseases it may cause. PUVA is a gamble, a calculated risk.


Mycosis Fungoides Alopecia Areata Xeroderma Pigmentosum Vitiligo Patient PUVA Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Al-Saleem, R., Ali, Z.S., and Qassah, M., 1980, Skin cancers in xeroderma pigmentosum: response to indomethacin and steroids. Lancet, ii: 264.CrossRefGoogle Scholar
  2. Arlett, C.F., Heddle, J.A., Broughton, B.C., and Rogers, A.M., 1980, Cell killing and mutagenesis by 8-methoxypsoralen in mammalian (rodent) cells. Clin. Exp. Dermatol., 5: 147.PubMedCrossRefGoogle Scholar
  3. Ashwood-Smith, M.J., Grant, E.L., Heddle, J.A., and Friedman, G.B., 1977, Chromosome damage in Chinese hamster cells sensitized to near-ultraviolet light by psoralen and angelicin, Mutation Res., 43: 377.PubMedCrossRefGoogle Scholar
  4. Baltimore, D., 1974, Is terminal deoxynucleotidyl transferase a somatic mutagen for lymphocytes?, Nature, 248: 409.PubMedCrossRefGoogle Scholar
  5. Bridges, B.A., 1978, Possible long-term hazards of photochemotherapy with psoralens and near-ultraviolet light, Clin. Exp. Dermatol., 3: 349.PubMedCrossRefGoogle Scholar
  6. Bridges, B.A., 1979, An estimate of genetic risk from 8-methoxypsoralen photochemotherapy, Hum. Genet., 49: 91.PubMedGoogle Scholar
  7. Bridges, B.A. and Strauss, G.H., 1980, Possible hazards of photochemotherapy for psoriasis, Nature, 218: 523.CrossRefGoogle Scholar
  8. Bridges, B.A., Greaves, M., Polani, P.E., and Wald, N., in press, Do treatments available for psoriasis patients carry a genetic or carcinogenic risk? A report from an expert group of the International Commission for Protection against Environmental Mutagens and Carcinogens, Mutation Res. and Biol. Zentr.Google Scholar
  9. Bridges, B.A., Strauss, G.H., Hall-Smith, P., and Price, M., 1981, Induction of somatic mutations and impairment of immune capacity by PUVA treatment and their relation to skin cancer in man, in: “Psoralens in Cosmetics and Dermatology”, Pergamon Press, Paris.Google Scholar
  10. Catalona, W.J., Taylor, P.T. and Chretieu, P.B., 1972, Quantitative dinitrochlorobenzene contact sensitization in a normal population, Clin. Exp. Immunol., 12: 325.PubMedGoogle Scholar
  11. Cormane, R.H., Hamerlinck, F. and Siddiqui, A.H., 1979, Immunologic implications of PUVA therapy in psoriasis vulgaris, Arch. Dermatol. Res., 265: 275.CrossRefGoogle Scholar
  12. Evans, D.L., and Morrow, R.J., 1979, 8-methoxypsoralen induced alterations of mammalian cells, J. Invest. Dermatol., 72: 35.PubMedCrossRefGoogle Scholar
  13. Griffin, A.C., 1959, Methoxsalen in ultraviolet carcinogenesis in the mouse. J. Invest. Dermatol. 31: 367.CrossRefGoogle Scholar
  14. Igali, S., Bridges, B.A., Ashwood-Smith, M.J., and Scott, B.R., 1970, Mutagenesis in Escherichia coli IV, Photosensitization to near-ultraviolet light by 8-methoxypsoralen, Mutation Res., 9: 21.PubMedCrossRefGoogle Scholar
  15. Kerkis, J.J., and Skorova, S.V., 1973, Humoral factors of “spontaneous” mutagenesis in mammals and man. Mutation Res., 18: 179.PubMedCrossRefGoogle Scholar
  16. Kinlin, L., et al., 1979, Collaborative United Kingdom/Australian study of cancer patients treated with immunosuppressive drugs, Brit. Med. J., 2: 1461.CrossRefGoogle Scholar
  17. Kraemer, R.H. and Weinstein, G.D., 1977, Decreased thymidine incorporation in circulating leukocytes after treatment of psoriasis with psoralen and long-wave ultraviolet light, J. Invest. Dermatol., 69: 211.PubMedCrossRefGoogle Scholar
  18. Malling, H.V., 1976, Mutagenesis testing: mammalian systems. Mutation Res., 41: 171.CrossRefGoogle Scholar
  19. Melski, J.W., Tanenbaum, L., Parrish, J.A., et al., 1977, Oral methoxsalen photochemotherapy for the treatment of psoriasis: a co-operative clinical trial, J. Invest. Dermatol., 68: 328.PubMedCrossRefGoogle Scholar
  20. Morhenn, V.B., Benike, B.S., and Engleman, E.G., 1980, Inhibition of cell mediated immune response by 8-methoxypsoralen and long-wave ultraviolet light: a possible explanation for the clinical effects of photo-activated psoralens, J. Invest. Dermatol., 75: 249.PubMedCrossRefGoogle Scholar
  21. Morison, W.L., Woehler, M.E., and Parrish, J.A., 1979, PUVA and systemic immunosuppression in guinea pigs. J. Invest. Dermatol., 72: 273.Google Scholar
  22. Morison, W.L., Parrish, J.A., McAuliffe, D.J. and Bloch, K.J., 1981, Sensitivity of mononuclear cells to PUVA: effect on subsequent stimulation with mitogens and on exclusion of trypan blue dye, Clin. Exp. Dermatol., 6: 273.PubMedCrossRefGoogle Scholar
  23. Parrish, J.A., Fitzpartick, T.B., Tanenbaum, L., and Pathak, M.A., 1974, Photochemotherapy for psoriasis with oral methoxsalen and longwave ultraviolet light, New Engl. J. Med., 291: 1207.PubMedCrossRefGoogle Scholar
  24. Parrish, J.A., LeVine, M.J., and Fitzpatrick, T.B., 1980, Oral methoxsalen photochemotherapy of psoriasis and mycosis fungoides, Int. J. Dermatol., 19: 379.PubMedCrossRefGoogle Scholar
  25. Reed, W.D., 1976, Treatment of psoriasis with oral psoralens and longwave ultraviolet light, Acta Dermato-vener., 56: 315.Google Scholar
  26. Roberts, L.K., Schmitt, M., and Daynes, R.A., 1979, Tumour susceptibility generated in mice treated with subcarcinogenic doses of 9-methoxypsoralen and longwave ultraviolet light, J. Invest. Dermatol., 72: 306.PubMedCrossRefGoogle Scholar
  27. Stern, R.S., Thibodeau, L.A., Kleinerman, R.A., Parrish, J.A., Fitzpatrick, et al., 1979, Risk of cutaneous carcinoma in patients treated with oral methoxsalen photochemotherapy for psoriasis, New. Engl. J. Med., 300–309.Google Scholar
  28. Strauss, G.H., in press, PUVA-Gambling with a system? Int. J. Dermatol.Google Scholar
  29. Strauss, G.H., and Albertini, R.J., 1979, Enumeration of 6-thioguanine peripheral blood lymphocytes as a potential test for somatic cell mutations arising in vivo, Mutation Res., 61: 353.PubMedCrossRefGoogle Scholar
  30. Strauss, G.H., Albertini, R.J., Krusinki, P.A., and Baughman, R.D., 1979, 6-thioguanine-resistant peripheral blood lymphocytes in humans following psoralen longwave UV light therapy, J. Invest. Dermatol., 73: 211.PubMedCrossRefGoogle Scholar
  31. Strauss, G.H., Bridges, B.A., Greaves, M., Hall-Smith, P., Price, M., and Vella-Briffa, D. 1980, Inhibition of delayed hypersensitivity reaction in skin (DNCB test) by 8-methoxypsoralen photochemotherapy: possible basis for pseudo-promoting action in skin carcinogenesis? Lancet, 2: 556.PubMedCrossRefGoogle Scholar
  32. Svejgaard, A., Nielsen, L., Svejgaard, E., Kissmeyer-Nielsen, F., Hjortshcj, A., and Zachariae, H., 1974, HL-A in psoriasis vulgaris and in pustular psoriasis-population and family studies, Brit. J. Dermatol., 91: 145.CrossRefGoogle Scholar
  33. Toews, G., Borgstresser, P.R., and Streilein, J.W., 1980, Epidermal Langerhans cell density determines whether contact hypersensitivity or unresponsiveness follows skin painting with DNFB, J. Immunol., 124: 445.PubMedGoogle Scholar
  34. Updike, J., 1979, From the journal of a leper, in: “Problems and Other Stories”, Knopf, New York.Google Scholar
  35. Vella-Briffa, D., and Warin, A.P., 1979, Photochemotherapy in psoriasis: A review, J. R. Soc. Med., 72: 440.Google Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • G. H. S. Strauss
    • 1
  1. 1.Centre for Medical Research and MRC Cell Mutation UnitUniversity of SussexBrightonEngland

Personalised recommendations